#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy. The results, released in a ...
Summit Therapeutics at #ASCO2026 (Karen Weintraub for Endpoints News) May 31, 2026 08:00 AM EDTUpdated 12:34 PM R&D Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means Max Gelman Senior Editor CHICAGO — The leading drug in biopharma’s hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that